Abstract：Objective To observe the clinical effect of Dapagliflozin combined with Berberine in the treatment of fragile type 2 diabetes. Methods A selection of 60 patients with fragile type 2 diabetes who were admitted to Huai’an Cancer Hospital in Jiangsu Province from April 2018 to March 2020 were randomly divided into observation group (30 cases) and control group (30 cases) by coin flipping. The control group was given intensive insulin therapy alone, and the observation group was treated with Dapagliflozin + Berberine. The lipid metabolism and body mass index (triacylglycerol [TG], total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C], body weight [BW], body mass indexes [BMI]) before and after treatment between the two groups were compared, and treatments changes in blood glucose and insulin control indicators (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], 2 h postprandial blood glucose [2hPG], fasting insulin [FINS], C peptide [CP]), blood glucose fluctuations (postprandial blood glucose fluctuation amplitude [PPGE], mean absolute difference of blood sugar [MODD], standard deviation of blood sugar level [SDBG]), blood pressure and daily use of insulin [systolic blood pressure (SBP), diastolic blood pressure (DBP), daily use of insulin] were compared before and after treatment. The occurrence of adverse reactions between the two groups was compared. Results After treatment, the levels of TG, TC, LDL-C, BW, and BMI in the two groups were lower than before treatment, while the observation group were lower than the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, the levels of HbA1c, FPG, and 2hPG in the two groups were lower than before treatment, while FINS and CP were higher than before treatment, and the levels of HbA1c, FPG, and 2hPG in the observation group were lower than those in the control group, while FINS and CP were higher than those in the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, PPGE, MODD, and SDBG in the two groups were lower than before treatment, while the observation group were lower than the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, the daily consumption levels of SAP, DAP, and daily use of insulin in the two groups were lower than before treatment, while the observation group were lower than the control group, and the differences were statistically significant (P ＜ 0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Dapagliflozin combined with Berberine has a significant effect in the treatment of patients with fragile type 2 diabetes, which can improve blood sugar levels and has high drug safety.
周洁 吴新华 马立明 严妍 时雯 李行 朱平. 达格列净联合黄连素治疗脆性2型糖尿病的临床观察[J]. 中国医药导报, 2021, 18(15): 75-78,83.
ZHOU Jie WU Xinhua MA Liming YAN Yan SHI Wen LI Hang ZHU Ping. Clinical observation of Dapagliflozin combined with Berberine in the treatment of fragile type 2 diabetess. 中国医药导报, 2021, 18(15): 75-78,83.
京公网安备 11010502046598号